JP2018501288A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018501288A5 JP2018501288A5 JP2017536302A JP2017536302A JP2018501288A5 JP 2018501288 A5 JP2018501288 A5 JP 2018501288A5 JP 2017536302 A JP2017536302 A JP 2017536302A JP 2017536302 A JP2017536302 A JP 2017536302A JP 2018501288 A5 JP2018501288 A5 JP 2018501288A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- halo
- group
- independently selected
- ring
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 0 *C(C(CN(*)CC1)C1O*)=O Chemical compound *C(C(CN(*)CC1)C1O*)=O 0.000 description 52
- OSOUNOBYRMOXQQ-UHFFFAOYSA-N Cc1cccc(Cl)c1 Chemical compound Cc1cccc(Cl)c1 OSOUNOBYRMOXQQ-UHFFFAOYSA-N 0.000 description 5
- NPDACUSDTOMAMK-UHFFFAOYSA-N Cc(cc1)ccc1Cl Chemical compound Cc(cc1)ccc1Cl NPDACUSDTOMAMK-UHFFFAOYSA-N 0.000 description 3
- CWOMTHDOJCARBY-UHFFFAOYSA-N Cc1cccc(N(C)C)c1 Chemical compound Cc1cccc(N(C)C)c1 CWOMTHDOJCARBY-UHFFFAOYSA-N 0.000 description 3
- NNZRVXTXKISCGS-UHFFFAOYSA-N CC(C)c(cccc1)c1OC Chemical compound CC(C)c(cccc1)c1OC NNZRVXTXKISCGS-UHFFFAOYSA-N 0.000 description 2
- HHAISVSEJFEWBZ-UHFFFAOYSA-N CC(c1ccc(C(F)(F)F)cc1)=O Chemical compound CC(c1ccc(C(F)(F)F)cc1)=O HHAISVSEJFEWBZ-UHFFFAOYSA-N 0.000 description 2
- LFWPYXVUTPBBFO-UHFFFAOYSA-N Cc1cc(cccc2OC)c2cc1 Chemical compound Cc1cc(cccc2OC)c2cc1 LFWPYXVUTPBBFO-UHFFFAOYSA-N 0.000 description 2
- LRLRAYMYEXQKID-UHFFFAOYSA-N Cc1ccc(C(F)(F)F)cc1 Chemical compound Cc1ccc(C(F)(F)F)cc1 LRLRAYMYEXQKID-UHFFFAOYSA-N 0.000 description 2
- QPUYECUOLPXSFR-UHFFFAOYSA-N Cc1cccc2ccccc12 Chemical compound Cc1cccc2ccccc12 QPUYECUOLPXSFR-UHFFFAOYSA-N 0.000 description 2
- NVWKNAHSBCFIJJ-UHFFFAOYSA-N CC(C)(C)c(cc1)cnc1-c1ccccc1 Chemical compound CC(C)(C)c(cc1)cnc1-c1ccccc1 NVWKNAHSBCFIJJ-UHFFFAOYSA-N 0.000 description 1
- CNGDMFQIKXDHNO-UHFFFAOYSA-N CC(C)(C)c1cc(cccc2)c2c(C(N)=O)c1 Chemical compound CC(C)(C)c1cc(cccc2)c2c(C(N)=O)c1 CNGDMFQIKXDHNO-UHFFFAOYSA-N 0.000 description 1
- CQXHSFGOGVESJT-UHFFFAOYSA-N CC(C)C(CCC1)CN1C1CCC1 Chemical compound CC(C)C(CCC1)CN1C1CCC1 CQXHSFGOGVESJT-UHFFFAOYSA-N 0.000 description 1
- UJHIOLUOUDCINT-UHFFFAOYSA-N CC(C)c(cc1)ccc1Oc1ccccc1 Chemical compound CC(C)c(cc1)ccc1Oc1ccccc1 UJHIOLUOUDCINT-UHFFFAOYSA-N 0.000 description 1
- ZHJXMVDNGJWXGZ-UHFFFAOYSA-N CC(C)c(cc1)cnc1-c1ccccc1 Chemical compound CC(C)c(cc1)cnc1-c1ccccc1 ZHJXMVDNGJWXGZ-UHFFFAOYSA-N 0.000 description 1
- LEAFFFRTMHCZJL-UHFFFAOYSA-N CC(C)c1cc(cccc2)c2c(C(N)=O)c1 Chemical compound CC(C)c1cc(cccc2)c2c(C(N)=O)c1 LEAFFFRTMHCZJL-UHFFFAOYSA-N 0.000 description 1
- UHMPRRDOKNUULU-UHFFFAOYSA-N CC(CCC1)CN1C(C1)CC1(F)F Chemical compound CC(CCC1)CN1C(C1)CC1(F)F UHMPRRDOKNUULU-UHFFFAOYSA-N 0.000 description 1
- ZQLRRBSHZGMLGZ-UHFFFAOYSA-N CC(CCC1)CN1C(CC1)CC1C(CCN(C1)C2CCOCC2)C1N Chemical compound CC(CCC1)CN1C(CC1)CC1C(CCN(C1)C2CCOCC2)C1N ZQLRRBSHZGMLGZ-UHFFFAOYSA-N 0.000 description 1
- RYJIXAHENDOEPH-UHFFFAOYSA-N CC(CCC1)CN1C1CCN(C)CC1 Chemical compound CC(CCC1)CN1C1CCN(C)CC1 RYJIXAHENDOEPH-UHFFFAOYSA-N 0.000 description 1
- KAOJZDBVQFDETF-UHFFFAOYSA-N CC(CCC1)CN1C1COC1 Chemical compound CC(CCC1)CN1C1COC1 KAOJZDBVQFDETF-UHFFFAOYSA-N 0.000 description 1
- LCTNPUZDOIMCGM-UHFFFAOYSA-N CC(CCC1)CN1S(C)(=O)=O Chemical compound CC(CCC1)CN1S(C)(=O)=O LCTNPUZDOIMCGM-UHFFFAOYSA-N 0.000 description 1
- FZRKUTKTDQEIIJ-UHFFFAOYSA-N CC(NCc1cc(C)cc2c1cccc2)=O Chemical compound CC(NCc1cc(C)cc2c1cccc2)=O FZRKUTKTDQEIIJ-UHFFFAOYSA-N 0.000 description 1
- CAMLJDZKPYMXOK-UHFFFAOYSA-N CC1CN(CCO)CCC1 Chemical compound CC1CN(CCO)CCC1 CAMLJDZKPYMXOK-UHFFFAOYSA-N 0.000 description 1
- YIRIERBVWIOARY-UHFFFAOYSA-N CCCN1CC(C)CCC1 Chemical compound CCCN1CC(C)CCC1 YIRIERBVWIOARY-UHFFFAOYSA-N 0.000 description 1
- UTNUBFLRANNOGC-ZIJQAHPGSA-N CC[C@@H](CCN(C1)C2CCC2)[C@@H]1C(c1ccc(C(CC#N)C(C=C2)OC)c2c1)=O Chemical compound CC[C@@H](CCN(C1)C2CCC2)[C@@H]1C(c1ccc(C(CC#N)C(C=C2)OC)c2c1)=O UTNUBFLRANNOGC-ZIJQAHPGSA-N 0.000 description 1
- IVYXIZSSLAKIFL-SBUREZEXSA-N CC[C@@H](CCN(C1)C2CCC2)[C@H]1C(c(ccc1c2CC#N)cc1ccc2OC)=O Chemical compound CC[C@@H](CCN(C1)C2CCC2)[C@H]1C(c(ccc1c2CC#N)cc1ccc2OC)=O IVYXIZSSLAKIFL-SBUREZEXSA-N 0.000 description 1
- IVYXIZSSLAKIFL-UZUQRXQVSA-N CC[C@H](CCN(C1)C2CCC2)[C@@H]1C(c(ccc1c2CC#N)cc1ccc2OC)=O Chemical compound CC[C@H](CCN(C1)C2CCC2)[C@@H]1C(c(ccc1c2CC#N)cc1ccc2OC)=O IVYXIZSSLAKIFL-UZUQRXQVSA-N 0.000 description 1
- IVYXIZSSLAKIFL-HXOBKFHXSA-N CC[C@H](CCN(C1)C2CCC2)[C@H]1C(c(ccc1c2CC#N)cc1ccc2OC)=O Chemical compound CC[C@H](CCN(C1)C2CCC2)[C@H]1C(c(ccc1c2CC#N)cc1ccc2OC)=O IVYXIZSSLAKIFL-HXOBKFHXSA-N 0.000 description 1
- SRQOBNUBCLPPPH-UHFFFAOYSA-N CCc(cc1)ccc1-c1ccccc1 Chemical compound CCc(cc1)ccc1-c1ccccc1 SRQOBNUBCLPPPH-UHFFFAOYSA-N 0.000 description 1
- BJDGGDWQTYWFQS-KSFYIVLOSA-N C[C@@H](CCN(C1)C2CCC2)[C@@H]1C(c(ccc1c2CC#N)cc1ccc2OC)=O Chemical compound C[C@@H](CCN(C1)C2CCC2)[C@@H]1C(c(ccc1c2CC#N)cc1ccc2OC)=O BJDGGDWQTYWFQS-KSFYIVLOSA-N 0.000 description 1
- BJDGGDWQTYWFQS-ZHRRBRCNSA-N C[C@H](CCN(C1)C2CCC2)[C@H]1C(c(ccc1c2CC#N)cc1ccc2OC)=O Chemical compound C[C@H](CCN(C1)C2CCC2)[C@H]1C(c(ccc1c2CC#N)cc1ccc2OC)=O BJDGGDWQTYWFQS-ZHRRBRCNSA-N 0.000 description 1
- GVZXWYGZNBWRID-UHFFFAOYSA-N C[IH]C(CCC1)CN1C(C1)CC1C#N Chemical compound C[IH]C(CCC1)CN1C(C1)CC1C#N GVZXWYGZNBWRID-UHFFFAOYSA-N 0.000 description 1
- ZZLCFHIKESPLTH-UHFFFAOYSA-N Cc(cc1)ccc1-c1ccccc1 Chemical compound Cc(cc1)ccc1-c1ccccc1 ZZLCFHIKESPLTH-UHFFFAOYSA-N 0.000 description 1
- IBSQPLPBRSHTTG-UHFFFAOYSA-N Cc(cccc1)c1Cl Chemical compound Cc(cccc1)c1Cl IBSQPLPBRSHTTG-UHFFFAOYSA-N 0.000 description 1
- AMBXKWBHIFZZRB-UHFFFAOYSA-N Cc1cc(cccc2)c2c(CN)c1 Chemical compound Cc1cc(cccc2)c2c(CN)c1 AMBXKWBHIFZZRB-UHFFFAOYSA-N 0.000 description 1
- NPDIDUXTRAITDE-UHFFFAOYSA-N Cc1cccc(-c2ccccc2)c1 Chemical compound Cc1cccc(-c2ccccc2)c1 NPDIDUXTRAITDE-UHFFFAOYSA-N 0.000 description 1
- APVQRVSBMIDSFS-UHFFFAOYSA-N Cc1cccc(Oc(cc2)ccc2F)c1 Chemical compound Cc1cccc(Oc(cc2)ccc2F)c1 APVQRVSBMIDSFS-UHFFFAOYSA-N 0.000 description 1
- IWIBDSGNVAVVCF-UHFFFAOYSA-N N#CCN(CCC1)CC1I Chemical compound N#CCN(CCC1)CC1I IWIBDSGNVAVVCF-UHFFFAOYSA-N 0.000 description 1
- GQCDDPVGVWVCPP-UHFFFAOYSA-N N#Cc1cc(I)cc2c1cccc2 Chemical compound N#Cc1cc(I)cc2c1cccc2 GQCDDPVGVWVCPP-UHFFFAOYSA-N 0.000 description 1
- CWVITUDPTUTLBV-UHFFFAOYSA-N NC(CCC1)CN1C1COCC1 Chemical compound NC(CCC1)CN1C1COCC1 CWVITUDPTUTLBV-UHFFFAOYSA-N 0.000 description 1
- CUHJBJNQMDQQAS-UHFFFAOYSA-N OCc1cc(I)cc2c1cccc2 Chemical compound OCc1cc(I)cc2c1cccc2 CUHJBJNQMDQQAS-UHFFFAOYSA-N 0.000 description 1
- PNXPCGKYMCUCEJ-UHFFFAOYSA-N c(cc1)ccc1C1=C[I]=CC=C1 Chemical compound c(cc1)ccc1C1=C[I]=CC=C1 PNXPCGKYMCUCEJ-UHFFFAOYSA-N 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562101927P | 2015-01-09 | 2015-01-09 | |
| US62/101,927 | 2015-01-09 | ||
| PCT/US2016/012638 WO2016112284A1 (en) | 2015-01-09 | 2016-01-08 | (piperidin-3-yl)(naphthalen-2-yl)methanone derivatives and related compounds as inhibitors of the histone demethylase kdm2b for the treatment of cancer |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018501288A JP2018501288A (ja) | 2018-01-18 |
| JP2018501288A5 true JP2018501288A5 (enExample) | 2019-02-14 |
| JP6855379B2 JP6855379B2 (ja) | 2021-04-07 |
Family
ID=55299746
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017536302A Expired - Fee Related JP6855379B2 (ja) | 2015-01-09 | 2016-01-08 | 癌の処置のためのヒストンデメチラーゼｋｄｍ２ｂのインヒビターとしての（ピペリジン−３−イル）（ナフタレン−２−イル）メタノン誘導体および関連化合物 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US10280149B2 (enExample) |
| EP (1) | EP3242872B1 (enExample) |
| JP (1) | JP6855379B2 (enExample) |
| CN (1) | CN107406414B (enExample) |
| WO (1) | WO2016112284A1 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2018183586A1 (en) * | 2017-03-29 | 2018-10-04 | Purdue Research Foundation | Inhibitors of kinase networks and uses thereof |
| CA3092357A1 (en) * | 2018-03-14 | 2019-09-19 | Prelude Therapeutics, Incorporated | Selective inhibitors of protein arginine methyltransferase 5 (prmt5) |
| EP4149917B1 (en) * | 2020-05-12 | 2025-07-30 | Merck Sharp & Dohme LLC | Factor xi activation inhibitors |
| CN117177972A (zh) * | 2021-04-19 | 2023-12-05 | 新特拉有限公司 | Parp1抑制剂及其用途 |
Family Cites Families (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CU22545A1 (es) | 1994-11-18 | 1999-03-31 | Centro Inmunologia Molecular | Obtención de un anticuerpo quimérico y humanizado contra el receptor del factor de crecimiento epidérmico para uso diagnóstico y terapéutico |
| LU77659A1 (de) * | 1977-06-30 | 1979-03-26 | Byk Gulden Lomberg Chem Fab | Piperidinoadamantane,verfahren zu ihrer herstellung und sie enthaltende arzneimittel |
| US4943533A (en) | 1984-03-01 | 1990-07-24 | The Regents Of The University Of California | Hybrid cell lines that produce monoclonal antibodies to epidermal growth factor receptor |
| DE69025946T2 (de) | 1989-09-08 | 1996-10-17 | Univ Duke | Modifikationen der struktur des egf-rezeptor-gens in menschlichen glioma |
| AU661533B2 (en) | 1992-01-20 | 1995-07-27 | Astrazeneca Ab | Quinazoline derivatives |
| GB9314893D0 (en) | 1993-07-19 | 1993-09-01 | Zeneca Ltd | Quinazoline derivatives |
| ATE207366T1 (de) | 1993-12-24 | 2001-11-15 | Merck Patent Gmbh | Immunokonjugate |
| IL112249A (en) | 1994-01-25 | 2001-11-25 | Warner Lambert Co | Pharmaceutical compositions containing di and tricyclic pyrimidine derivatives for inhibiting tyrosine kinases of the epidermal growth factor receptor family and some new such compounds |
| US5654307A (en) | 1994-01-25 | 1997-08-05 | Warner-Lambert Company | Bicyclic compounds capable of inhibiting tyrosine kinases of the epidermal growth factor receptor family |
| IL112248A0 (en) | 1994-01-25 | 1995-03-30 | Warner Lambert Co | Tricyclic heteroaromatic compounds and pharmaceutical compositions containing them |
| KR100441557B1 (ko) | 1994-07-21 | 2005-08-05 | 아크조 노벨 엔.브이. | 고리형케톤과산화물조성물 |
| US5804396A (en) | 1994-10-12 | 1998-09-08 | Sugen, Inc. | Assay for agents active in proliferative disorders |
| ATE446955T1 (de) | 1995-03-30 | 2009-11-15 | Pfizer Prod Inc | Chinazolinone derivate |
| GB9508538D0 (en) | 1995-04-27 | 1995-06-14 | Zeneca Ltd | Quinazoline derivatives |
| GB9508565D0 (en) | 1995-04-27 | 1995-06-14 | Zeneca Ltd | Quiazoline derivative |
| US5747498A (en) | 1996-05-28 | 1998-05-05 | Pfizer Inc. | Alkynyl and azido-substituted 4-anilinoquinazolines |
| CA2222231A1 (en) | 1995-06-07 | 1996-12-19 | Imclone Systems Incorporated | Antibody and antibody fragments for inhibiting the growth of tumors |
| PL188959B1 (pl) | 1995-07-06 | 2005-05-31 | Novartis Ag | Pirolopirymidyny i sposoby ich wytwarzania |
| US5760041A (en) | 1996-02-05 | 1998-06-02 | American Cyanamid Company | 4-aminoquinazoline EGFR Inhibitors |
| GB9603095D0 (en) | 1996-02-14 | 1996-04-10 | Zeneca Ltd | Quinazoline derivatives |
| CN100503580C (zh) | 1996-04-12 | 2009-06-24 | 沃尼尔·朗伯公司 | 酪氨酸激酶的不可逆抑制剂 |
| US6391874B1 (en) | 1996-07-13 | 2002-05-21 | Smithkline Beecham Corporation | Fused heterocyclic compounds as protein tyrosine kinase inhibitors |
| ID18494A (id) | 1996-10-02 | 1998-04-16 | Novartis Ag | Turunan pirazola leburan dan proses pembuatannya |
| UA73073C2 (uk) | 1997-04-03 | 2005-06-15 | Уайт Холдінгз Корпорейшн | Заміщені 3-ціанохіноліни, спосіб їх одержання та фармацевтична композиція |
| US6002008A (en) | 1997-04-03 | 1999-12-14 | American Cyanamid Company | Substituted 3-cyano quinolines |
| US6235883B1 (en) | 1997-05-05 | 2001-05-22 | Abgenix, Inc. | Human monoclonal antibodies to epidermal growth factor receptor |
| AU7165698A (en) | 1997-05-06 | 1998-11-27 | American Cyanamid Company | Use of quinazoline compounds for the treatment of polycystic kidney disease |
| ZA986729B (en) | 1997-07-29 | 1999-02-02 | Warner Lambert Co | Irreversible inhibitors of tyrosine kinases |
| ZA986732B (en) | 1997-07-29 | 1999-02-02 | Warner Lambert Co | Irreversible inhibitiors of tyrosine kinases |
| TW436485B (en) | 1997-08-01 | 2001-05-28 | American Cyanamid Co | Substituted quinazoline derivatives |
| AU1308799A (en) | 1997-11-06 | 1999-05-31 | American Cyanamid Company | Use of quinazoline derivatives as tyrosine kinase inhibitors for treating colonic polyps |
| CN1160338C (zh) | 1998-11-19 | 2004-08-04 | 沃尼尔·朗伯公司 | N-[4-(3-氯-4-氟-苯基氨基)-7-(3-吗啉-4-基-丙氧基)-喹唑啉-6-基]-丙烯酰胺,不可逆的酪氨酸激酶抑制剂 |
| CA2389049A1 (en) * | 1999-09-27 | 2001-04-05 | Georgetown University | Dopamine transporter inhibitors and their use |
| PE20071079A1 (es) * | 2005-11-15 | 2007-12-16 | Cytokinetics Inc | Compuestos de piperidina como inhibidores de la proliferacion celular |
| US8541572B2 (en) * | 2008-11-10 | 2013-09-24 | Merck Sharp & Dohme Corp. | Compounds for the treatment of inflammatory disorders |
| WO2012071469A2 (en) * | 2010-11-23 | 2012-05-31 | Nevada Cancer Institute | Histone demethylase inhibitors and uses thereof for treatment o f cancer |
| WO2013123411A1 (en) * | 2012-02-17 | 2013-08-22 | Board Of Regents, The University Of Texas System | Methods for diagnosing and treating cancer |
| ES2644828T3 (es) * | 2013-03-15 | 2017-11-30 | Quanticel Pharmaceuticals Inc | Inhibidores de histona desmetilasa |
-
2016
- 2016-01-08 WO PCT/US2016/012638 patent/WO2016112284A1/en not_active Ceased
- 2016-01-08 CN CN201680014364.2A patent/CN107406414B/zh not_active Expired - Fee Related
- 2016-01-08 EP EP16702830.7A patent/EP3242872B1/en active Active
- 2016-01-08 JP JP2017536302A patent/JP6855379B2/ja not_active Expired - Fee Related
-
2017
- 2017-07-07 US US15/643,808 patent/US10280149B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2489148C2 (ru) | Ингибитор активации stat3/5 | |
| JP2020023528A5 (enExample) | ||
| JP2005519908A5 (enExample) | ||
| JP2005047930A5 (enExample) | ||
| RU2012108423A (ru) | Ацилгуанидиновые производные с азотсодержащим циклом | |
| CN109328187A (zh) | 一种具有fgfr抑制活性的新型化合物及其制备和应用 | |
| JP2018524390A5 (enExample) | ||
| JP2016040288A5 (enExample) | ||
| JP2011132222A5 (enExample) | ||
| CA2416274A1 (en) | N-phenyl-2-pyrimidine-amine derivatives | |
| RU2011108281A (ru) | Трипиридилкарбоксамидные антагонисты орексиновых рецепторов | |
| JP2014051526A5 (enExample) | ||
| RU2015133989A (ru) | Ингибирующие jak соединения на основе пиразолопиримидина и способы | |
| RU2018106453A (ru) | Соединения | |
| RU2009115954A (ru) | Пиразолопиримидины в качестве ингибиторов липидной киназы р13к | |
| JP2016506935A5 (enExample) | ||
| JP2017504635A5 (enExample) | ||
| JP2012510467A5 (enExample) | ||
| JP2011524850A5 (enExample) | ||
| RU2011124304A (ru) | Ингибиторы протеинкиназ (варианты), их применение для лечения онкологических заболеваний и фармацевтическая композиция на их основе | |
| CA2713025A1 (en) | Kappa selective opioid receptor antagonist | |
| JP2008517923A5 (enExample) | ||
| JP2019505529A5 (enExample) | ||
| JP2017505293A5 (enExample) | ||
| JP2019508496A5 (enExample) |